



NO ACCESS NO THREAT

NEW!

THE ZOETIS MILK FLOW
GUARANTEE

Ask Zoetis for details

OrbeSeal aids in the prevention of new intramammary infections throughout the dry period.



CLINICAL EFFECTS AND ECONOMIC BENEFIT of an internal teat sealant at dry-off

Paul Baillargeon¹ and Stephen LeBlanc².

THE BOVINE PRACTITIONER - VOL.44, NO.1

INTRODUCTION

Treating all quarters of all cows with a long-acting, dry-cow antibiotic at the time of dry-off is widely recommended in North America.

Although a keratin plug typically seals the teat after dry-off, 23% of teats, and up to 46% in high producing cows, are still open 6 weeks later³.

In North America, an internal teat sealant (ITS) used with antimicrobial dry-cow therapy (ADCT) was shown to decrease new intramammary infections (IMI) by 30% and clinical mastitis (CM) in the first 60 days by 33%⁴.

An average economic benefit of US\$5.38 per cow was reported in a study in 3 herds in Wisconsin⁵.

“The objective of this clinical trial was to **compare the efficacy and economic benefit of OrbeSeal + antibiotic dry cow treatment** versus antibiotic dry cow treatment alone in reducing the incidence of clinical mastitis in early lactation.”



METHODS

- 1,334 cows from 12 dairy farms were randomly assigned to ADCT or ADCT + OrbeSeal treatments in all 4 quarters at dry-off.
- Only cows with dry periods of 28 to 120 days were included.
- Cows were monitored for CM from calving to 105 DIM.
- Milk samples were cultured from CM cases.
- Production data were obtained from herds' computerized health records (VALACTA; DSA).
- Data including herd, parity, treatment group, dates of calving, CM, culling, milk culture results, and DHI data from the first 3 tests of lactation were analyzed in multivariable logistic, Poisson and Cox statistical models.
- Economic analysis was conducted using Cook's method⁶ with milk price = \$0.71 CDN/L and cost of ITS = \$10 CDN/cow.



First cases of CM and incidence rate of CM (IRCM) from calving to 105 DIM for the treatment groups ADCT + OrbeSeal and ADCT alone.

	ADCT + OrbeSeal	ADCT
No. of cows	665	669
No. of 1 st cases of CM before 105 days (%)	97 (15%)	125 (19%)
	(RR) = 0.78, 95% CI 0.61 to 0.99, P = 0.05	
IRCM (no. of cases/100 cow-days at risk)	.16	.21
	(RR)= 0.78; 95% CI 0.61 to 1.01, P = 0.06	

RESULTS

ADCT + OrbeSeal
(accounting for parity, season and herd)

- ▶ Statistical analysis of the data showed that the risk of CM decreased by **25%**.
- ▶ **39%** less likely to have clinical coliform mastitis.
- ▶ **No difference** in risk of CM caused by Streptococci.
- ▶ Net **economic benefit** of the OrbeSeal group of \$20 CDN per cow.

CONCLUSION

Under field conditions, ADCT+OrbeSeal at dry-off lowered the incidence of CM between calving and 105 DIM by approximately 25%.

The impact is particularly significant for the risk of mastitis caused by *E.coli*.

On average in the present study, adding OrbeSeal to the established dry-cow treatment profitably reduced the incidence of CM at the start of lactation.

- At all times, dry-cow materials should be kept away or shielded from possible fecal/urine contamination.
- Disposable gloves should be worn during the disinfection process.
- OrbeSeal must be stored at room temperature (between 60°F-85°F, 15°C-30°C).
- If OrbeSeal becomes difficult to administer in extremely cold weather, it should be warmed to room temperature before use.

Individual tubes should not be immersed in water.

- OrbeSeal requires no milk or preslaughter withdrawal. If OrbeSeal is used in conjunction with a dry-cow mastitis treatment program, follow the labelled withdrawal period of the antibiotic.



References

1. Zoetis, Kirkland, Quebec, Canada.
2. Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
3. Dingwell, R.T., D.F. Kelton, K.E. Leslie. Management of the dry cow in control of peripartum disease and mastitis. *Vet Clin Food Anim* 19:235–265, 2003.
4. Godden, S, P. Rapnicki, S. Stewart, J. Fetrow, A. Johnson, R. Bey, R. Farnsworth. Effectiveness of an internal teat seal in the prevention of new intramammary infections during the dry and early-lactation periods in dairy cows when used with a dry-cow intramammary antibiotic. *J Dairy Sci* 86:3899-3911, 2003.
5. Cook, N.B., D.A. Pionek, P Sharp. An assessment of the benefits of OrbeSeal® when used in combination with dry-cow antibiotic therapy in three commercial dairy herds. *Bov Prac* 39:83-94, 2005.

Acknowledgement

This study was supported by Zoetis Canada. We are grateful to the producers and practitioners whose participation made the study possible.

